AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 61 min read$LH

Kyle Kathryn W sold $26K of LH

Kyle Kathryn W (EVP, Chief Legal Officer) sold 92 shares of LABCORP HOLDINGS INC. (LH) at $286.19 on 2026-07-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kyle Kathryn W
Published Jul 6, 2026, 1:37 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 6, 2026, 1:39 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$LH
Neutral
high confidence
Mentioned
$LH
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LHNeutralLow
01

Why it matters

Because the sale is explicitly under a pre-arranged Rule 10b5-1 plan, it typically reflects scheduled liquidity rather than new negative information.

02

Market read

A small, scheduled insider sale is unlikely to drive trading decisions beyond routine monitoring.

03

What to watch

The article provides only one transaction size and does not include prior insider activity frequency, option exercises, or any concurrent buys.

Relevance 2/10Novelty 3/10Timing: Filed July 6, covering a sale executed July 2

Background

The disclosure is an SEC Form 4 insider transaction by Kyle Kathryn W (EVP, Chief Legal Officer) for LABCORP HOLDINGS INC.

Company-level read

Ticker impact

$LHNeutralHigh confidence
Context

Form 4 shows LH’s EVP & Chief Legal Officer sold 92 shares at $286.19 on a 10b5-1 plan, totaling $26,329.48.

Expected impact

Minimal near-term impact; any effect is likely sentiment-only and short-lived.

Evidence & confidence

The filing is an open-market sale by an insider with an explicitly stated 10b5-1 plan and small share count/value relative to typical market moves.

Market effects

Sector

No clear sector read-through from a single, small 10b5-1 insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with 10b5-1, repeated insider selling can coincide with internal caution; traders may still monitor for a pattern.

Key entities

  • issuer
    LABCORP HOLDINGS INC.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Kyle Kathryn W

    EVP, Chief Legal Officer who executed the open-market sale.

Read at source← All news

Related articles

AUG 8
$LHMedAI 9/10

Labcorp (LH) Q2 2026 Earnings Call Transcript

Labcorp (LH) reported Q2 2026 enterprise revenue of $3.7B, up 5.8% Y/Y, with adjusted operating margin at 15.8% and adjusted EPS of $4.99, up 14.9%. Free cash flow was $314M. The company raised full-year guidance for revenue and adjusted EPS, citing Diagnostics and Central Laboratories strength.

aol.com10 min
AUG 5
$LHMed

Approved PTEN IHC Companion Diagnostic for Prostate Cancer

Labcorp said it has nationwide availability of Roche’s Ventana PTEN (SP218) RxDx immunohistochemistry companion diagnostic, FDA approved to detect PTEN protein loss in prostate adenocarcinoma. The result helps identify patients eligible for AstraZeneca’s TRUQAP (capivasertib) plus abiraterone acetate and prednisone. Labcorp says it supports personalized treatment decisions via its lab network.

clpmag.com3 min
AUG 5
$LHMed

LABCORP HOLDINGS 2026: Revenue $3.73B, EPS $3.64— 10-Q Summary

Labcorp Holdings (LH) reported Q2 2026 revenue of $3.73B and diluted EPS of $3.64, up from $3.53B and $2.84 a year earlier, according to its 10-Q. The company cited higher test utilization, price and mix gains, and margin expansion, plus 4.2% organic growth and acquisition contributions. It also increased capital spending and completed acquisitions.

tradingview.com1 min
AUG 5
$LHMed

Labcorp launches FDA-approved PTEN test for prostate cancer

Labcorp (NYSE:LH) said the FDA-approved Roche VENTANA PTEN (SP218) RxDx Assay is now available nationwide. The test detects PTEN protein loss in prostate adenocarcinoma tissue to identify patients who may qualify for AstraZeneca’s TRUQAP (capivasertib) with abiraterone and prednisone, according to Labcorp. The assay is offered via Labcorp’s lab network.

investing.com3 min
AUG 4
$LHMedAI 9/10

Labcorp (LH) Q2 2026 Earnings Call Transcript

Labcorp (LH) reported Q2 2026 enterprise revenue of $3.7B, up 5.8% YoY, with adjusted EPS of $4.99, up 14.9%. Adjusted operating margin rose to 15.8%. Free cash flow was $314M. The company raised full-year guidance for revenue and adjusted EPS, citing Diagnostics and Central Laboratories strength, and noted ACA headwinds.

fool.com10 min
JUL 31
$LHHighAI 9/10

Labcorp (LH) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 9:00 a.m. ET CALL PARTICIPANTS Senior Vice President, Investor Relations - Dewey Steadman Chairman and Chief Executive Officer - Adam Schechter Executive Vice President and Chief Financial Officer - Julia Wang TAKEAWAYS Enterprise Revenue -- $3.7 billion, up 5.8% year over year, driven by 4.2% organic growth and 1.2% contribution from net acquisitions.

fool.com6 min